Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A group of invasive breast carcinomas characterized by the presence of an adenocarcinomatous component which is admixed with a dominant component that is composed of squamous cells, spindle cells, or mesenchymal cells.
Biomarker and diagnostic research for metaplastic breast carcinoma has been reported in the published literature.
3 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE2. Research is primarily sponsored by academic and government institutions.
88 publications have been identified in PubMed for metaplastic breast carcinoma. Research spans Case Report / Case Series (44%), Basic Science / Preclinical (14%), and Epidemiology / Natural History (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 39 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:15 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research | 12 | 14% |
Disease patterns and progression | 11 | 13% |
Testing and diagnosis research | 9 | 10% |
Clinical study results | 9 | 10% |
Research summaries | 7 | 8% |
New treatment approaches | 1 | 1% |
Ara U (2026). [PMID: 42083686](https://pubmed.ncbi.nlm.nih.gov/42083686/). *Cureus*. [Epidemiology / Natural History]
Pan F (2026). [PMID: 42074958](https://pubmed.ncbi.nlm.nih.gov/42074958/). *J Clin Med*. [Diagnostic / Biomarker]
Zhang N (2026). [PMID: 41940823](https://pubmed.ncbi.nlm.nih.gov/41940823/). *Clin Nucl Med*. [Diagnostic / Biomarker]
Hettwer CC (2026). [PMID: 40645909](https://pubmed.ncbi.nlm.nih.gov/40645909/). *Clinical breast cancer*. [Review / Meta-Analysis]
Xu J (2026). [PMID: 41839236](https://pubmed.ncbi.nlm.nih.gov/41839236/). *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. [Clinical Trial Publication]
Talat F (2026). [PMID: 42077680](https://pubmed.ncbi.nlm.nih.gov/42077680/). *Cureus*. [Case Report / Case Series]
Naveed H (2026). [PMID: 42249684](https://pubmed.ncbi.nlm.nih.gov/42249684/). *Int J Surg Pathol*. [Case Report / Case Series]
Chu W (2026). [PMID: 42180112](https://pubmed.ncbi.nlm.nih.gov/42180112/). *Front Oncol*. [Case Report / Case Series]
Caindec AM (2026). [PMID: 41891932](https://pubmed.ncbi.nlm.nih.gov/41891932/). *Int J Surg Pathol*. [Case Report / Case Series]
Ye R (2026). [PMID: 41737540](https://pubmed.ncbi.nlm.nih.gov/41737540/). *Breast cancer (Dove Medical Press)*. [Basic Science / Preclinical]
AI-curated news mentioning metaplastic breast carcinoma
Updated Aug 24, 2026
A recent study provides insights into metaplastic breast cancer through a single-center retrospective analysis. The findings contribute to the understanding of this rare subtype of breast cancer, although specific data points were not detailed.
A case report and literature review highlight the multimodal imaging evaluation of early-stage metaplastic breast carcinoma with heterologous mesenchymal differentiation. This study contributes to the understanding of imaging techniques in rare breast cancer subtypes.
A case report highlights the long-term response to pembrolizumab in a patient with metastatic metaplastic breast carcinoma. This finding may inform future treatment strategies for this rare breast cancer subtype.